Shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) dropped -25.77% by the end of trading session at $3.86. The net percentage change is -28.65% over the last 12 months. The trading range in the same period had a highest hit of $7.39 while lowest level was $3.55. At the moment the price is -28.98% below its 50-day moving average and -25.77% below its 200-day moving average.

Osiris Therapeutics, Inc. (NASDAQ:OSIR) on February 10, 2016 announced that its Board of Directors, at a Board Meeting on February 7th, 2017, confirmed the appointment of Messrs. Uwe Sommer and Thomas J. Knapp as Directors, upon recommendation of the Nominating Committee, and each will stand for election at the Company’s 2017 Stockholders’ Meeting.  Mr. Sommer and Mr. Knapp each join Osiris as independent Board members.

Mr. Sommer is a highly experienced leader in global marketing and sales, managing distribution in markets including Europe, Japan, the Middle East, Africa, and the United States.  Mr. Sommer has held executive roles with Johnson & Johnson, Lindt & Sprüngli, Mars, Inc., and Procter & Gamble.  Mr. Sommer has degrees in Economics from University Kiel (Germany) and Marketing and Economics from Penn State University.

Mr. Knapp has over 25 years of corporate and large legal firm experience with regulated industries, with experience including Federal and State regulatory matters, Federal government affairs, risk management, compliance, litigation, complex commercial transactions, and corporate governance.  Mr. Knapp is presently Interim General Counsel and Corporate Secretary with Galena Biopharma, Inc., prior to which his experience includes serving as EVP, Chief Legal Officer, and Corporate Secretary of Sucampo Pharmaceuticals, Inc., as Vice President, General Counsel and Corporate Secretary at NorthWestern Corporation, and in senior in-house attorney positions at The Boeing Company and The Burlington Northern & Santa Fe Railway Company.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) last exchanged hands at a price $7.25/share, registering a decline of -3.97%. Among 7 Wall Street analysts tracked by Thomson/First Call, the average PT for FOLD is $11.07 but some of them are predicting the price to move at the $15 level. If the most optimistic analysts are correct, the expected total return from the current price would be 106.9. The number of shares traded in most recent trading day was 2.91M shares which averages 3.74M shares a day. Its previous fifty two week high was $9.83 and moved down -8.34% over the same time frame, currently having a market cap around $1.03 billion. Shares have risen 19.83% over the trailing six months. At the moment, the stock trades 21.28% above its 50-day moving average and 10.15% above its 200-day moving average.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) on March 8, 2017 reported that it has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (Ministero della Salute). Galafold is now reimbursed in Italy as a therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation.

Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A), which is the result of mutations in the GLA gene. As a precision medicine, Galafold is designed to restore alpha-Gal A activity in patients who have amenable mutations (an estimated 35% to 50% of the Fabry population).

The European Commission granted full approval for Galafold on May 30, 2016, as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.